Adrian Gottschalk, Foghorn Therapeutics CEO (Flagship via YouTube)
June 28, 2023 11:11 AM EDT
R&D

With just one re­sponse in 47 pa­tients, Foghorn stops work on lead can­di­date in ad­vanced eye can­cer

Lei Lei Wu

News Reporter

Foghorn Ther­a­peu­tics said Wednes­day morn­ing that it was stop­ping fur­ther work on an ex­per­i­men­tal drug for a rare ad­vanced eye can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times